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This prospective study examines whether a patient medication instruction sheet (PMI) given
to clinic patients by their health care provider affects knowledge and/or attitudes with thiazide
diuretic use as part of an antihypertensive regimen.
Adult male patients (N = 285) in a general medicine clinic were assigned to groups receiving
the American Medical Association PMI describing their diuretic. Patients getting the PMI
obtained it either directly from their provider or at the pharmacy dispensing window. All patients
were surveyed by phone 1 week following the clinic visit with regard to the PMI, knowledge
of medication use, and attitudes toward drug use.
Results indicate that a provider-dispensed PMI results in higher levels of drug knowledge
and greater patient satisfaction with their knowledge than a pharmacy-dispensed PMI. In addition,
the PMIs educational value may be lessened by an incomplete verbal consult. This study
demonstrates that the AMA PMI is an effective educational tool when distributed by a provider
and can promote better understanding and use of prescribed medications.
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INTRODUCTION
Most physicians, pharmacists, and other health care professionals agree that patients
should be educated about their drug therapy and encouraged to participate in medical
decisions, but much controversy exists concerning the best method(s) for accomplishing
this goal. During the 1970s, the patient package insert (PPI) was widely promotcd as
a way to increase patient knowledge and to encourage proper use of medications.
Some suggested that the PPI might enhance medication compliance, decrease adverse
side effects, and improve patient-provider communications.’ Others were skeptical
that PPIs could achieve these objectives, arguing that these messages probably would
not be read or, if read, that they would promote inappropriate self-medication, foster
prescription drug exchange among patients, produce suggestion-induced side effects
in &dquo;susceptible&dquo; individuals, and alarm patients to the point of their disregarding needed
drug therapy. 1.2
Research in this area has now demonstrated that: patients desire written information
about their niedication S3,4; the majority of patients read the information they receive5-’;
written information can improve patients’ knowledge about their therapy 2-&dquo; and the
best effects are achieved when both verbal and written information are presented 2- 1;
the amount of physician-patient contact time is not significantly affected by giving
the patient a PPI6; PPIs improve compliance in short-course antibiotic therapy 2 but
results are mixed with regard to drug regimens for chronic conditions.2
Although these investigations produced some promising results, the FDA rescinded
a proposed program requiring PPI distribution for a select group of drugs in 1982.
This decision was based on evaluations of the PPI program (including those sponsored
by the FDA) that suggested that PPIs would be expensive and that the cost would not
be justified since PPIs would not significantly alter patients’ established drug use
patterns, influence their decisions about whether to take medication, increase com-
pliance, or encourage the reporting of side effects. 10 However, other organizations
continued to provide written drug information in response to consumer demand.
One approach that has generated considerable interest among consumers and health
professionals is the Patient Medication Instruction (PMI) program of the American
Medical Association (AMA). Advocates of the program assert that written information
provided at the time the drug is prescribed (rather than at the pharmacy dispensing
window) should strengthen the physician-patient relationship, reduce improper drug
use, decrease the incidence of preventable and serious adverse drug reactions, and
improve patient compliance. Unlike the FDA PPI program, the cost is nominal ($0.50
to physician per pad of 100 PMI drug sheets), and the time/effort required to use the
PMI during a visit is minimal.&dquo;
Because the PMI program is currently being promoted as superior to the package-
based information sheets, we have gathered data relevant to the following issues:
1. Does the environment in which written information is dispensed matter (i.e.,
will whether the PMI is given to the patient by the provider or at the pharmacy
dispensing window affect patient knowledge, attitudes, and use of a chronic
medication)’?
2. Does type of provider influence the effects of the PMI’?




The study population consisted of 285 adult male hypertensive patients who attended
the outpatient general medicine clinics at a Veterans Administration Medical Center.
Patients ranged in age from 35-79 years, with a mean age of 60.6 years. Any patient
receiving a new or refill prescription for a thiazide diuretic as part of his antihypertensive
regimen was included. Informed consent forms were placed in all patients’ charts in
the general medicine clinics at the beginning of each day. When a provider encountered
a patient receiving a thiazide diuretic, that patient was asked to participate in the study
by reading and signing the consent form.
Study Design
Patients were assigned to one of three experimental groups or the control group over
a 4-month period. Groups were run consecutively by month.
By the end of the first month, 93 patients had met the study criteria and were
assigned to the control group. These patients received no special information about
their diuretic during the course of the study. During the second study month, 54
patients were assigned to group I. Patients in this group received written drug infor-
mation at the pharmacy dispensing window in a bag along with their medication
(pharmacy/PMI). The written information used in this study was the Patient Medication
Information sheet on thiazide diuretics published by the AMA. It describes in layman’s
terms uses and actions of the medication, proper administration, and precautions. It
also describes medication side effects, specifying those that should be reported to a
doctor and those that may not require immediate attention.
Seventy-nine patients met study criteria during the third study month and were
assigned to group II. Group II patients received their PMI from a provider (pro-
vider/PMI). Six staff physicians, three physician assistants, and two clinical phar-
macists served as providers in the study. Finally, during the fourth month of the study,
59 patients were assigned to group III. Patients in this group received both the PMI
and a verbal consult from their provider (PMI/consult); the latter was a standardized
consult based on information that is commonly discussed with patients about their
diuretic during typical office visits (APPENDIX).
A six-page telephone interview (lasting about 20 minutes) was developed and pre-
tested to assess the effects of the PMI and consult. The items in the interview focused
on four main topics. ,
Attitudes toward Use of the PMI
These questions were designed to evaluate both patient satisfaction with various
aspects of the PMI and the extent to which patients were making use of it. For example,
patients were asked if they had read the PMI, had gone back to it at any time, felt
they knew more since receiving it, wanted more information.
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Perceived Drug Knowledge
These questions measured how much the patients thought they knew about the
diuretic and how to take it. For example, patients were asked to rate, on a five-point
scale, how satisfied they were with their knowledge of various issues relating to their
diuretic, such as directions for use, possible side effects, what to do about side effects,
and what foods to eat or avoid.
Objective Knowledge of Diuretic Therapy and Hypertension
These questions were designed to assess the actual levels of patient knowledge
regarding the information presented in the PMI. For example, patients were asked to
respond to open-ended questions concerning directions for use, side effects, foods to
eat and avoid, and problems caused by untreated hypertension.
Experience with and Attitudes toward Side Effects
This topic included such questions as whether the patient had ever experienced side
effects, what side effects he had experienced, and how concerned he was about side
effects.
Each patient was interviewed approximately I week after his clinic visit. Patients
who had received a PMI were explicitly discouraged from retrieving it for use during
the interview.
Scoring
Although most of the interview items were closed ended, eight questions obtained
open-ended responses. One of these items concerned which side effects the patient
might have had experienced: the others assessed the patient’s knowledge of PMI
information. Patients’ responses were coded according to one of two methods. For
those questions to which multiple correct answers were expected, patients received a
score corresponding to the number of correct responses they gave to each question.
For the other items, patients’ answers were simply scored as either correct or incorrect
(&dquo;don’t know&dquo; answers were coded as incorrect). Some patients responded with answers
that could be correct but were not covered in the PMI, these responses were excluded
from the analyses.
For each patient, an overall knowledge score was created by dividing the number
of correct answers by the total number of questions asked. The numerator included
all knowledge questions for which at least one correct answer was given by the patient.
Analyses
The statistical test employed in our analyses was the Goodman-Kruskal y, a non-
parametric bivariate measure of linear correlation. This statistic ranges from - I (per-
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fect negative correlation) through 0 (complete independence) to + I (perfect positive
correlation). In this article, the sign of correlation is given as positive when the
correlation is in the expected direction and negative when opposite to the direction
hypothesized.
RESULTS
Attitudes toward and Use of the PMI 
’
Findings concerning PMI utilization and perceived need for more information are
summarized in Table 1.
By combining the reports of patients in groups I (pharmacy/PMI) and II (pro-
vider/PMI), responses reflect the effect of the PMI alone: 81.9°~0 of these patients
reported having read the PMI, and 72.3% felt that they knew more after receiving it.
In addition, only 20.9% felt that they needed more information about their diuretic,
as opposed to 38.2% of patients who did not receive a PMI, a significant difference
(y = 0.40; p < 0.01 ). Further analysis revealed that 92% of patients having received
a PMI had it 1 to 2 weeks later and that the majority of patients were satisfied with
the informational content. These results may be somewhat better than those that would
normally be obtained outside the study setting; since the patients knew they were
participating in research, some may have felt a greater obligation to read the PMI. In
practice, however, the same effect might be accomplished by having the provider ask
the patient to read the PMI.
One significant difference was found among the three experimental groups. Group
III (PMI/consult) patients were more likely to refer back to the PMI than were patients
in groups I and II (y = 0.45; p < 0.01 ).
Table l. Attitudes toward and Use of the PMI (by Study Group)
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Satisfaction with Knowledge Acquisition
Table 2 presents the data concerning patient satisfaction with perceived drug knowl-
edge.
Patients in the experimental groups were significantly more satisfied than the control
group with their overall perceived drug knowledge (p < 0.0001 ). However, within
the experimental groups, differences are not large, nor are they very consistent. The
main distinction seems to be that group I (pharmacy/PMI) patients were generally less
satisfied than were patients who received their PMI from a provider (groups II and
-111).
Additional insights on the topic of perceived knowledge acquisition are provided
by findings in Table 3, which presents patients’ responses to questions concerning
how much people at the clinic told them about the same four items covered in Table
2. As anticipated, patients who were given a provider consult (group III) reported
receiving more information at clinic than did patients in either group I or II. What is
interesting is that this difference was also obtained for the two items about side effects,
since information concerning side effects was not included in the standardized consult
(APPENDIX) but rather was providcd in the PMI. It would seem that, when a verbal
consult is presented in conjunction with a PMI, the patient’s perception of the scope
of information given in the consult expands to assimilate information that was in fact
learned by having read the PMI.
Objective Knowledge Acquisition
Results concerning patients’ actual knowledge acquisition are summarized in Table
4.
Overall, patients in the experimental groups scored higher on objective knowledge
than patients in the control group. The only exception involved responses to a question
concerning what serious problems could be caused by untreated hypertension: on this
Table 2. Patient Satisfaction with Acquired Knowledge (by Study Group)
’’Rating scalc: I = not at all satisfied, 5 = very satisfied.
hp <o. I o.
~p <0.05.
dp < 0 . 0001.
57
Table 3. Perceived Knowledge Acquisition (by Study Group)





Table 4. Objective Knowledge Acquisition (by Study Group)
’Figures are mean number of correct responses per patient.
’Figures are percentage of patients answering question corrcctly.






item, control patients performed about as well as patients in any of the experimental
groups. A possible explanation for this unexpected finding is the introduction, within
the last several years, of considerable information in the mass media informing the
public of the dangers of uncontrolled hypertension (thus enabling the controls to achieve
higher scores on this item).
Within the experimental groups, it might have been expected that group III patients
(PMI/consult) would have scored higher than group I (pharmacy/PMI) or group II
(provider/PMI) patients. However, this was not the case. Further analyses revealed
that group II patients performed the best with group III intermediate and group I scoring
lowest (the correlation for the overall score was significant at the 0.002 level). These
findings may result from the fact that the questions asked during the interview dealt
with information contained only in the PMI and not in the provider consult. Thus, it
is possible that the consult may have had the effect of making the additional information
in the PMI seem less important to that patient, since it was not reviewed by the
provider.
Experience with and Attitudes toward Side Effects
Table 5 presents findings regarding side effects.
Although patients in groups I-III were significantly more likely than were control
patients to report having experienced side effects and to report more side effects per
patient on the average (~ < 0.002), there was essentially no difference in rating of
concern.
Effects of Provider Type
Separate analyses were performed on patients in groups II and III (i.e., patients
receiving their PMI from a provider) to determine whether provider type (MD, PA,
Table 5. Experience of and Attitudes toward Side Effects (by Study Group)
’Figures are percentage of patients answering &dquo;Ycs.&dquo;
bFigures are mean number of correct side effects (defined as side effects listed in PM1) reported
by patient.




PharmD) had any effect on patients’ responses. Virtually no significant differences
were found, indicating that for the kind of limited patient-provider interactions used
in this study, type of provider is not a very important factor.
DISCUSSION 
’
Should providers be involved in educating patients regarding the benefits and risks
of drug therapy or in the dispensing of PMIs’? This investigation demonstrated that
the AMA PMI can be an effective educational tool when distributed by a provider
with or without a verbal consult. Although it has often been claimed that patients will
not bother to read drug information, our study (and others’-’) found that the written
information (PMI) given to patients was read in the majority (>80%) of cases. Fur-
thermore, we determined that over 90% of our patients still had the PMI in their
possession 2 weeks after receiving it.
Results indicate that patients who get their PMI from a provider are more likely
(p < 0.05) to continue to use it than are those patients who receive the PMI as a
package insert in the bag with their medications at the pharmacy dispensing window.
It may be that the personal attention given to these patients makes the PMI seem more
important. A potentially confounding factor, however, may exist with regard to the
content of the consult given to study patients. Group III (consult) patients referred
back to the PMI more often, yet scored lower on objective knowledge questions that
did group II (provider/PMI) patients. We speculate that in order for a consult to enhance
the PMIs educational value, the provider must verbally communicate the PMI infor-
mation with which he would like the patient to become familiar; patients seem to
attach importance only to the verbally transmitted information, and it is only that
information on the PMI that is reinforced (and, therefore, easier to retain). On the
other hand, patients who receive a PMI from their provider without an accompanying
consult may be more inclined to perceive all of the PMI information as important and
will review the entire content more carefully (thus actually learning more than do
patients in the &dquo;consult&dquo; group). Further study of the value of more complete consults
is needed.
Results of our interview are consistent with previous research on PPIs, which found
higher levels of knowledge of drug use and side effects among patients who received
written information than among those who did not. 4.5 Furthermore, our data show that
patients’ satisfaction with their diuretic knowledge was greatly enhanced when they
obtained their PMI from a provider, especially with regard to information received on
foods to eat or to avoid when using a diuretic. Objective knowledge acquisition was
significantly improved in all areas (with the exception of the question concerning
consequences of uncontrolled hypertension) when the PMIs were dispensed to patients
by their providers.
Our findings support investigations indicating that patients prefer to receive drug
information from physicians. 5.12 It should be noted, however, that in this study, patient
satisfaction with drug knowledge and objective acquisition were not significantly mod-
ified by the type of provider with whom the patient interacted.
Providing information about side effects may well increase patient reporting of those
side effects but does not increase patient concern. These data suggest that listing side
effects in the PMI should not adversely affect a patient’s drug-taking behavior. The
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results indicate that a PMI can have a positive impact on patient education and may
be effectively utilized by the patient’s health care provider to promote better under-
standing and use of prescribed medications.
APPENDIX
Standardized Consultation
~ (Name of drug) is a diuretic, also known as a &dquo;water pill.&dquo; .
~ This medicine is used in the treatment of high blood pressure.
w Since this medicine may make you urinate more frequently, you should take your
water pill in the morning (or if you are taking more than one dose, no later than
6 PM in the evening).
. While you are taking this medicine, you should reduce the amount of salt that
you use; you may use a salt substitute.
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